Weighing QoL and Toxicity in 1L EGFRm NSCLC Treatment Decisions

Quality-of-Life and Toxicity Considerations

Main Discussion Topics:

• Comparative toxicity profiles of available treatment regimens
• Impact of adverse effects on patient QoL
• Prophylactic strategies to mitigate treatment-related adverse events

Key Points for Physicians:

• Osimertinib monotherapy is extremely well tolerated with minimal impact on daily life
• FLAURA2 (chemotherapy + osimertinib) has more intensive induction followed by manageable maintenance
• Amivantamab + lazertinib has unique toxicities, including scalp rash, paronychia, hypoalbuminemia, and venous thromboembolism risk

Notable Insights:

Prophylactic strategies (COCOON for dermatologic toxicities; SKIPPirr for infusion reactions, anticoagulation) can significantly reduce adverse events with amivantamab/lazertinib.

Clinical Significance:

Selection of therapy requires careful assessment of toxicity profiles in the context of patient comorbidities, support systems, and preferences regarding appearance and lifestyle impact.